Markella V Zanni

发表

Characteristics of REPRIEVE Trial Participants Identifying Across the Transgender Spectrum.

P. Douglas, E. Gardner, Kathleen V Fitch, 2020, The Journal of infectious diseases.

Heart Failure among People with HIV: Evolving Risks, Mechanisms, and Preventive Considerations

T. Neilan, Markella V Zanni, Mabel Toribio, 2019, Current HIV/AIDS Reports.

Sex Differences in Subclinical Coronary Atherosclerotic Plaque Among Individuals With HIV on Antiretroviral Therapy

Michael T. Lu, T. Burdo, Kathleen V Fitch, 2018, Journal of acquired immune deficiency syndromes.

Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial.

G. Bloomfield, M. Kozal, K. Tashima, 2020, The Journal of infectious diseases.

Incidence, Predictors, and Outcomes of Implantable Cardioverter‐Defibrillator Discharge Among People Living With HIV

T. Neilan, R. Alvi, Noor Tariq, 2018, Journal of the American Heart Association.

Sex Differences in Circulating Biomarkers of Cardiovascular Disease.

D. Levy, P. Courchesne, M. Larson, 2019, Journal of the American College of Cardiology.

Follow YOUR Heart: development of an evidence-based campaign empowering older women with HIV to participate in a large-scale cardiovascular disease prevention trial

P. Douglas, J. Currier, Kathleen V Fitch, 2017, HIV clinical trials.

Elevated ischemic stroke risk among women living with HIV infection

J. Meigs, C. Bushnell, Sara E Looby, 2018, AIDS.

Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial

G. Bloomfield, C. Fichtenbaum, K. Ruxrungtham, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Regulatory Gene Mutations Affecting Apolipoprotein Gene Expression: Functions and Regulatory Behavior of Known Genes May Guide Future Pharmacogenomic Approaches to Therapy

D. Kardassis, Tong Liu, V. Zannis, 2003, Clinical chemistry and laboratory medicine.

Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE).

Michael T. Lu, C. Fichtenbaum, P. Douglas, 2019, American heart journal.

Subclinical myocyte injury, fibrosis and strain in relationship to coronary plaque in asymptomatic HIV-infected individuals

Michael T. Lu, U. Hoffmann, R. Christenson, 2016, AIDS.

TNF-alpha antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome.

R. Ahima, Hang Lee, S. Grinspoon, 2011, The Journal of clinical endocrinology and metabolism.

Risk of coronary heart disease in patients with HIV infection

P. Reiss, J. Schouten, S. Grinspoon, 2014, Nature Reviews Cardiology.

Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkers.

Michael T. Lu, C. Fichtenbaum, P. Douglas, 2019, American heart journal.